Evidence map›Paper›PMID 39300525›Full record

ArticleJournal of cardiothoracic surgery2024

Detection of serum SNHG22 and its correlation with prognosis of non-small cell lung cancer.

Quan Cheng, Guoping Chen, Xiaojiao Wu, Hang Fang, Jingjing Shi, Bonian Zhong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiothoracic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Quan Cheng *Department of Traditional Chinese Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, China.
Guoping Chen *Department of Respiratory and Critical Care Medicine, Binhai County People's Hospital, Yancheng, 224500, China.
Xiaojiao WuDepartment of Laboratory, The First People's Hospital of Yongkang, No. 52, Lizhou North Road, Yongkang, 321300, China. YKwuxiaojiao1986@163.com.
Hang FangDepartment of Laboratory, The First People's Hospital of Yongkang, No. 52, Lizhou North Road, Yongkang, 321300, China.
Jingjing ShiDepartment of Laboratory, The First People's Hospital of Yongkang, No. 52, Lizhou North Road, Yongkang, 321300, China.
Bonian ZhongDepartment of Pulmonary and Critical Care Medicine, The Fourth Affiliated Hospital of Guangzhou Medical University, No.1, Guangming East Road, Guangzhou, 511300, China. zhongbonian01@163.com.

Funding

Kangda College of Nanjing Medical University Research and Development Fund - Key Project No. KD2023KYJJ028
6 · The paper itself

Abstract

backgroundLung cancer accounts for a significant proportion of cancer-related deaths in China, with the majority of the cases being classified as non-small cell lung cancer (NSCLC). The study aimed to investigate the expression of serum SNHG22 in patients with NSCLC, and its molecular mechanism and prognostic potential in NSCLC.

methodsAdmitted 125 NSCLC patients were selected for the study, along with 125 healthy individuals in the same period. The levels of SNHG22 and miR-128-3p were quantified via RT-qPCR. Correlations between the SNHG22 level and the pathological characteristics of the NSCLC patients were investigated through the application of the chi-square test. The targeting relationship between SNHG22 and miR-128-3p was predicted by online database and confirmed by luciferase activity. The prognostic ability of SNHG22 in NSCLC was assessed by Kaplan-Meier curves and multivariate Cox analysis.

resultsSNHG22 was upregulated in NSCLC and directly targeted miR-128-3p. The rate of overall survival is lower in patients with high-SNHG22 group compared to those with low-SNHG22 group. Silencing SNHG22 impaired the functionality of cells, which was restored by miR-128-3p inhibitor. SNHG22 stands as an independent predictor of poor prognosis in NSCLC patients.

conclusionThe overexpression of SNHG22 in NSCLC is related to lymph node metastasis, TNM stage and patient survival, which is expected to be a prognostic predictor of NSCLC patients.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsMicroRNAsRNA, Long NoncodingAgedChinaFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, TumorMicroRNAsRNA, Long NoncodingBiological functionLung cancermiR-128-3pPrognosisSNHG22

Identifiers

PMID39300525
PMCPMC11414149

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.